메뉴 건너뛰기




Volumn 113, Issue 1, 2015, Pages 37-52

How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors - Is an algorithm the answer?

Author keywords

Clopidogrel; Platelet reactivity; Prasugrel; Ticagrelor

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450; PRASUGREL; PURINERGIC P2Y12 RECEPTOR INHIBITOR; PURINERGIC RECEPTOR BLOCKING AGENT; TICAGRELOR; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE;

EID: 84925359433     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-03-0238     Document Type: Review
Times cited : (50)

References (160)
  • 1
    • 84890025521 scopus 로고    scopus 로고
    • Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischaemia and bleeding
    • Tantry US, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischaemia and bleeding. J Am Coll Cardiol 2013; 62: 2261-2273.
    • (2013) J am Coll Cardiol , vol.62 , pp. 2261-2273
    • Tantry, U.S.1
  • 2
    • 84888106006 scopus 로고    scopus 로고
    • Response Variability to P2Y12 Receptor Inhibitors: Expectations and Reality
    • Siller-Matula JM, et al. Response Variability to P2Y12 Receptor Inhibitors: Expectations and Reality. JACC Cardiovasc Interv 2013; 6: 1111-1128.
    • (2013) JACC Cardiovasc Interv , vol.6 , pp. 1111-1128
    • Siller-Matula, J.M.1
  • 3
    • 60949083948 scopus 로고    scopus 로고
    • Platelet Reactivity After Clopidogrel Treatment Assessed With Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis
    • Sibbing D, et al. Platelet Reactivity After Clopidogrel Treatment Assessed With Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
    • (2009) J am Coll Cardiol , vol.53 , pp. 849-856
    • Sibbing, D.1
  • 4
    • 73949100670 scopus 로고    scopus 로고
    • Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions
    • Geisler T, et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010; 31: 59-66.
    • (2010) Eur Heart J , vol.31 , pp. 59-66
    • Geisler, T.1
  • 5
    • 74749094606 scopus 로고    scopus 로고
    • Multiple Electrode Aggregometry predicts stent thrombosis better than the VASP assay
    • Siller-Matula JM, et al. Multiple Electrode Aggregometry predicts stent thrombosis better than the VASP assay. J Thromb Haemost 2010; 8: 351-359.
    • (2010) J Thromb Haemost , vol.8 , pp. 351-359
    • Siller-Matula, J.M.1
  • 6
    • 34250020766 scopus 로고    scopus 로고
    • Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis
    • Buonamici P, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.
    • (2007) J am Coll Cardiol , vol.49 , pp. 2312-2317
    • Buonamici, P.1
  • 7
    • 73449106079 scopus 로고    scopus 로고
    • High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease
    • Migliorini A, et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation 2009; 120: 2214-2221.
    • (2009) Circulation , vol.120 , pp. 2214-2221
    • Migliorini, A.1
  • 8
    • 49349114160 scopus 로고    scopus 로고
    • Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents
    • Gori AM, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008; 52: 734-739.
    • (2008) J am Coll Cardiol , vol.52 , pp. 734-739
    • Gori, A.M.1
  • 9
    • 70349510067 scopus 로고    scopus 로고
    • Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients
    • Cuisset T, et al. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. Am J Cardiol 2009; 104: 1078-1082.
    • (2009) Am J Cardiol , vol.104 , pp. 1078-1082
    • Cuisset, T.1
  • 10
    • 8344221349 scopus 로고    scopus 로고
    • Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction
    • Matetzky S, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
    • (2004) Circulation , vol.109 , pp. 3171-3175
    • Matetzky, S.1
  • 11
    • 27644465874 scopus 로고    scopus 로고
    • Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST Study
    • Gurbel PA, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46: 1827-1832.
    • (2005) J am Coll Cardiol , vol.46 , pp. 1827-1832
    • Gurbel, P.A.1
  • 12
    • 33947495459 scopus 로고    scopus 로고
    • High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes
    • Cuisset T, et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost 2007; 97: 282-287.
    • (2007) Thromb Haemost , vol.97 , pp. 282-287
    • Cuisset, T.1
  • 13
    • 84886391924 scopus 로고    scopus 로고
    • Genetic variation of platelet function and pharmacology: An update of current knowledge
    • Geisler T, et al. Genetic variation of platelet function and pharmacology: An update of current knowledge. Thromb Haemost 2013; 110: 876-887.
    • (2013) Thromb Haemost , vol.110 , pp. 876-887
    • Geisler, T.1
  • 14
    • 56549090507 scopus 로고    scopus 로고
    • Platelet reactivity to adenosine diphosphate and long-term ischaemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target
    • Gurbel PA, et al. Platelet reactivity to adenosine diphosphate and long-term ischaemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets 2008; 19: 595-604.
    • (2008) Platelets , vol.19 , pp. 595-604
    • Gurbel, P.A.1
  • 15
    • 84859181019 scopus 로고    scopus 로고
    • Phenotyping vs. Genotyping for prediction of clopidogrel efficacy and safety: The PEGASUS-PCI study
    • Siller-Matula JM, et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost 2012; 10: 529-542.
    • (2012) J Thromb Haemost , vol.10 , pp. 529-542
    • Siller-Matula, J.M.1
  • 16
    • 33749503499 scopus 로고    scopus 로고
    • Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation
    • Geisler T, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425.
    • (2006) Eur Heart J , vol.27 , pp. 2420-2425
    • Geisler, T.1
  • 17
    • 33750479499 scopus 로고    scopus 로고
    • Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement
    • Hochholzer W, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
    • (2006) J am Coll Cardiol , vol.48 , pp. 1742-1750
    • Hochholzer, W.1
  • 18
    • 79960603731 scopus 로고    scopus 로고
    • High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes
    • Bonello L, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011; 58: 467-473.
    • (2011) J am Coll Cardiol , vol.58 , pp. 467-473
    • Bonello, L.1
  • 19
    • 67651173161 scopus 로고    scopus 로고
    • Pharmacodynamic assessment of platelet inhibition by prasugrel vs. Clopidogrel in the TRITON-TIMI 38 trial
    • Michelson AD, et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009; 30: 1753-1763.
    • (2009) Eur Heart J , vol.30 , pp. 1753-1763
    • Michelson, A.D.1
  • 20
    • 84866861394 scopus 로고    scopus 로고
    • Relationship between post-treatment platelet reactivity and ischaemic and bleeding events at one year follow-up in patients receiving prasugrel
    • Bonello L, et al. Relationship between post-treatment platelet reactivity and ischaemic and bleeding events at one year follow-up in patients receiving prasugrel. J Thromb Haemost 2012; 10: 1999-2005.
    • (2012) J Thromb Haemost , vol.10 , pp. 1999-2005
    • Bonello, L.1
  • 21
    • 80053630737 scopus 로고    scopus 로고
    • Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel
    • Alexopoulos D, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. Am Heart J 2011; 162: 733-739.
    • (2011) Am Heart J , vol.162 , pp. 733-739
    • Alexopoulos, D.1
  • 22
    • 82755162000 scopus 로고    scopus 로고
    • Antiplatelet Effects of Prasugrel vs Double Clopidogrel in Patients on Hemodialysis and High On-Treatment Platelet Reactivity
    • Alexopoulos D, et al. Antiplatelet Effects of Prasugrel vs Double Clopidogrel in Patients on Hemodialysis and High On-Treatment Platelet Reactivity. J Thromb Haemost 2011; 9: 2379-2385.
    • (2011) J Thromb Haemost , vol.9 , pp. 2379-2385
    • Alexopoulos, D.1
  • 23
    • 84873530056 scopus 로고    scopus 로고
    • Randomised Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment-Elevation Myocardial Infarction
    • Alexopoulos D, et al. randomised Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment-Elevation Myocardial Infarction. Circ Cardiovasc Interv 2012; 5: 797-804.
    • (2012) Circ Cardiovasc Interv , vol.5 , pp. 797-804
    • Alexopoulos, D.1
  • 24
    • 84875997213 scopus 로고    scopus 로고
    • Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study
    • Parodi G, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013; 61: 1601-1606.
    • (2013) J am Coll Cardiol , vol.61 , pp. 1601-1606
    • Parodi, G.1
  • 25
    • 74749097435 scopus 로고    scopus 로고
    • Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement
    • Sibbing D, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010; 8: 250-256.
    • (2010) J Thromb Haemost , vol.8 , pp. 250-256
    • Sibbing, D.1
  • 26
    • 77955603691 scopus 로고    scopus 로고
    • Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: Initial evidence of a therapeutic window
    • Sibbing D, et al. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol 2010; 56: 317-318.
    • (2010) J am Coll Cardiol , vol.56 , pp. 317-318
    • Sibbing, D.1
  • 27
    • 79958110089 scopus 로고    scopus 로고
    • Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome
    • Campo G, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011; 57: 2474-2483.
    • (2011) J am Coll Cardiol , vol.57 , pp. 2474-2483
    • Campo, G.1
  • 28
    • 77955715900 scopus 로고    scopus 로고
    • Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention
    • Mokhtar OA, et al. Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. Thromb Res 2010; 126: e147-149.
    • (2010) Thromb Res , vol.126 , pp. e147-e149
    • Mokhtar, O.A.1
  • 29
    • 84855852029 scopus 로고    scopus 로고
    • Residual Platelet Reactivity, Bleedings, and Adherence to Treatment in Patients Having Coronary Stent Implantation Treated With Prasugrel
    • Parodi G, et al. Residual Platelet Reactivity, Bleedings, and Adherence to Treatment in Patients Having Coronary Stent Implantation Treated With Prasugrel. Am J Cardiol 2012; 109: 214-218.
    • (2012) Am J Cardiol , vol.109 , pp. 214-218
    • Parodi, G.1
  • 30
    • 84882771753 scopus 로고    scopus 로고
    • Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: The POBA study (predictor of bleedings with antiplatelet drugs)
    • Cuisset T, et al. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). JACC Cardiovasc Interv 2013; 6: 854-863.
    • (2013) JACC Cardiovasc Interv , vol.6 , pp. 854-863
    • Cuisset, T.1
  • 31
    • 65349185008 scopus 로고    scopus 로고
    • Antiplatelet therapy in diabetes: Efficacy and limitations of current treatment strategies and future directions
    • Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 2009; 32: 531-540.
    • (2009) Diabetes Care , vol.32 , pp. 531-540
    • Angiolillo, D.J.1
  • 32
    • 37549006004 scopus 로고    scopus 로고
    • The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score
    • Geisler T, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008; 6: 54-61.
    • (2008) J Thromb Haemost , vol.6 , pp. 54-61
    • Geisler, T.1
  • 33
    • 80054919425 scopus 로고    scopus 로고
    • Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis
    • Cayla G, et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. J AmMed Assoc 2011; 306: 1765-1774.
    • (2011) J Ammed Assoc , vol.306 , pp. 1765-1774
    • Cayla, G.1
  • 34
    • 78651227746 scopus 로고    scopus 로고
    • Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy
    • Neubauer H, et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med 2011; 9: 3.
    • (2011) BMC Med , vol.9
    • Neubauer, H.1
  • 35
    • 79953296443 scopus 로고    scopus 로고
    • Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention
    • Htun P, et al. Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol 2011; 22: 627-633.
    • (2011) J am Soc Nephrol , vol.22 , pp. 627-633
    • Htun, P.1
  • 36
    • 77958466789 scopus 로고    scopus 로고
    • Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease
    • Muller K, et al. Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. Atherosclerosis 2010; 213: 256-262.
    • (2010) Atherosclerosis , vol.213 , pp. 256-262
    • Muller, K.1
  • 37
    • 54349121974 scopus 로고    scopus 로고
    • Calcium-channel blockers reduce the antiplatelet effect of clopidogrel
    • Siller-Matula JM, et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 52: 1557-1563.
    • (2008) J am Coll Cardiol , vol.52 , pp. 1557-1563
    • Siller-Matula, J.M.1
  • 38
    • 77952048536 scopus 로고    scopus 로고
    • The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response
    • Harmsze AM, et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 2010; 103: 920-925.
    • (2010) Thromb Haemost , vol.103 , pp. 920-925
    • Harmsze, A.M.1
  • 39
    • 77952591958 scopus 로고    scopus 로고
    • Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement
    • Hochholzer W, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010; 55: 2427-2434.
    • (2010) J am Coll Cardiol , vol.55 , pp. 2427-2434
    • Hochholzer, W.1
  • 40
    • 80053419318 scopus 로고    scopus 로고
    • Combined influence of proton-pump inhibitors, calciumchannel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention
    • Harmsze AM, et al. Combined influence of proton-pump inhibitors, calciumchannel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. J Thromb Haemost 2011; 9: 1892-1901.
    • (2011) J Thromb Haemost , vol.9 , pp. 1892-1901
    • Harmsze, A.M.1
  • 41
    • 38349065084 scopus 로고    scopus 로고
    • Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomised, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study
    • Gilard M, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomised, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260.
    • (2008) J am Coll Cardiol , vol.51 , pp. 256-260
    • Gilard, M.1
  • 42
    • 70049098599 scopus 로고    scopus 로고
    • Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomised study
    • Cuisset T, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomised study. J Am Coll Cardiol 2009; 54: 1149-1153.
    • (2009) J am Coll Cardiol , vol.54 , pp. 1149-1153
    • Cuisset, T.1
  • 43
    • 78349244351 scopus 로고    scopus 로고
    • Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: A systematic review and meta-analysis
    • Siller-Matula JM, et al. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost 2010; 8: 2624-2641.
    • (2010) J Thromb Haemost , vol.8 , pp. 2624-2641
    • Siller-Matula, J.M.1
  • 44
    • 57149104093 scopus 로고    scopus 로고
    • Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel
    • Siller-Matula JM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148.e1-.e5.
    • (2009) Am Heart J , vol.157 , Issue.148
    • Siller-Matula, J.M.1
  • 45
    • 84859524326 scopus 로고    scopus 로고
    • Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor
    • Teng R. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. Clin Pharmacokinet 2012; 51: 305-318.
    • (2012) Clin Pharmacokinet , vol.51 , pp. 305-318
    • Teng, R.1
  • 46
    • 84891896681 scopus 로고    scopus 로고
    • Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors
    • Siller-Matula JM, et al. Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors. J Thromb Haemost 2014; 12: 2-13.
    • (2014) J Thromb Haemost , vol.12 , pp. 2-13
    • Siller-Matula, J.M.1
  • 47
    • 84896694643 scopus 로고    scopus 로고
    • Morphine decreases clopidogrel concentrations and effects: A randomised, double-blind, placebo-controlled trial
    • Hobl EL, et al. Morphine decreases clopidogrel concentrations and effects: a randomised, double-blind, placebo-controlled trial. J Am Coll Cardiol 2014; 63: 630-635.
    • (2014) J am Coll Cardiol , vol.63 , pp. 630-635
    • Hobl, E.L.1
  • 48
    • 82955240702 scopus 로고    scopus 로고
    • CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients
    • Hulot JS, et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv 2011; 4: 422-428.
    • (2011) Circ Cardiovasc Interv , vol.4 , pp. 422-428
    • Hulot, J.S.1
  • 49
    • 61349191612 scopus 로고    scopus 로고
    • Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis
    • Giusti B, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 2009; 103: 806-811.
    • (2009) Am J Cardiol , vol.103 , pp. 806-811
    • Giusti, B.1
  • 50
    • 58249135635 scopus 로고    scopus 로고
    • Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study
    • Collet JP, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309-317.
    • (2009) Lancet , vol.373 , pp. 309-317
    • Collet, J.P.1
  • 51
    • 58749094444 scopus 로고    scopus 로고
    • Cytochrome p-450 polymorphisms and response to clopidogrel
    • Mega JL, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
    • (2009) N Engl J Med , vol.360 , pp. 354-362
    • Mega, J.L.1
  • 52
    • 69249219296 scopus 로고    scopus 로고
    • Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy
    • Shuldiner AR, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. J Am Med Assoc 2009; 302: 849-857.
    • (2009) J am Med Assoc , vol.302 , pp. 849-857
    • Shuldiner, A.R.1
  • 53
    • 84863703442 scopus 로고    scopus 로고
    • The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: The CHARISMA genetics study
    • Bhatt DL, et al. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J 2012: 33: 2143-2150.
    • (2012) Eur Heart J , vol.33 , pp. 2143-2150
    • Bhatt, D.L.1
  • 54
    • 81855211733 scopus 로고    scopus 로고
    • Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease
    • Mega JL, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. J Am Med Assoc 2011; 306: 2221-2228.
    • (2011) J am Med Assoc , vol.306 , pp. 2221-2228
    • Mega, J.L.1
  • 55
    • 58749090547 scopus 로고    scopus 로고
    • Genetic determinants of response to clopidogrel and cardiovascular events
    • Simon T, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375.
    • (2009) N Engl J Med , vol.360 , pp. 363-375
    • Simon, T.1
  • 56
    • 77957792195 scopus 로고    scopus 로고
    • CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: A case-control study
    • Harmsze AM, et al. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J 2010; 31: 3046-3053.
    • (2010) Eur Heart J , vol.31 , pp. 3046-3053
    • Harmsze, A.M.1
  • 57
    • 84862908606 scopus 로고    scopus 로고
    • Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin
    • Jeong YH, et al. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv 2011; 4: 585-594.
    • (2011) Circ Cardiovasc Interv , vol.4 , pp. 585-594
    • Jeong, Y.H.1
  • 58
    • 77958100874 scopus 로고    scopus 로고
    • Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial
    • Wallentin L, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-1328.
    • (2010) Lancet , vol.376 , pp. 1320-1328
    • Wallentin, L.1
  • 59
    • 76349098199 scopus 로고    scopus 로고
    • Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement
    • Sibbing D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121: 512-518.
    • (2010) Circulation , vol.121 , pp. 512-518
    • Sibbing, D.1
  • 60
    • 67949120411 scopus 로고    scopus 로고
    • The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome
    • Frere C, et al. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J Thromb Haemost 2009; 7: 1409-1411.
    • (2009) J Thromb Haemost , vol.7 , pp. 1409-1411
    • Frere, C.1
  • 61
    • 77958105401 scopus 로고    scopus 로고
    • Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis
    • Mega JL, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376: 1312-1319.
    • (2010) Lancet , vol.376 , pp. 1312-1319
    • Mega, J.L.1
  • 62
    • 84860879920 scopus 로고    scopus 로고
    • No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting
    • S1-2
    • Jaitner J, et al. No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting. Circ Cardiovasc Interv 2012; 5: 82-88, S1-2.
    • (2012) Circ Cardiovasc Interv , vol.5 , pp. 82-88
    • Jaitner, J.1
  • 63
    • 80053412474 scopus 로고    scopus 로고
    • Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention
    • Campo G, et al. Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention. J Thromb Haemost 2011; 9: 2106-2108.
    • (2011) J Thromb Haemost , vol.9 , pp. 2106-2108
    • Campo, G.1
  • 64
    • 0042859862 scopus 로고    scopus 로고
    • Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects
    • Fontana P, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989-995.
    • (2003) Circulation , vol.108 , pp. 989-995
    • Fontana, P.1
  • 65
    • 66349133650 scopus 로고    scopus 로고
    • Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes
    • Mega JL, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119: 2553-2560.
    • (2009) Circulation , vol.119 , pp. 2553-2560
    • Mega, J.L.1
  • 66
    • 34248397644 scopus 로고    scopus 로고
    • A double-blind, randomised study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days
    • von Beckerath N, et al. A double-blind, randomised study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007; 28: 1814-1819.
    • (2007) Eur Heart J , vol.28 , pp. 1814-1819
    • Von Beckerath, N.1
  • 67
    • 34948875324 scopus 로고    scopus 로고
    • Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease
    • Angiolillo DJ, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007; 50: 1541-1547.
    • (2007) J am Coll Cardiol , vol.50 , pp. 1541-1547
    • Angiolillo, D.J.1
  • 68
    • 38349137324 scopus 로고    scopus 로고
    • Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomised study
    • Angiolillo DJ, et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomised study. Thromb Haemost 2008; 99: 161-168.
    • (2008) Thromb Haemost , vol.99 , pp. 161-168
    • Angiolillo, D.J.1
  • 69
    • 58149476444 scopus 로고    scopus 로고
    • Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis
    • Bonello L, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009; 103: 5-10.
    • (2009) Am J Cardiol , vol.103 , pp. 5-10
    • Bonello, L.1
  • 70
    • 41249093357 scopus 로고    scopus 로고
    • Adjusted clopidogrel loading doses according to vasodilatorstimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomised prospective study
    • Bonello L, et al. Adjusted clopidogrel loading doses according to vasodilatorstimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomised prospective study. J Am Coll Cardiol 2008; 51: 1404-1411.
    • (2008) J am Coll Cardiol , vol.51 , pp. 1404-1411
    • Bonello, L.1
  • 71
    • 84883263516 scopus 로고    scopus 로고
    • Personalised antiplatelet treatment after percutaneous coronary intervention: The MADONNA study
    • Siller-Matula JM, et al. Personalised antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol 2013; 167: 2018-2023.
    • (2013) Int J Cardiol , vol.167 , pp. 2018-2023
    • Siller-Matula, J.M.1
  • 72
    • 59049103979 scopus 로고    scopus 로고
    • Antiplatelet response to the 150-mg maintenance dose of clopidogrel in patients with insufficient platelet inhibition after clopidogrel loading for elective coronary stent placement
    • Trenk D, et al. Antiplatelet response to the 150-mg maintenance dose of clopidogrel in patients with insufficient platelet inhibition after clopidogrel loading for elective coronary stent placement. EuroIntervention 2008; 4: 214-221.
    • (2008) Eurointervention , vol.4 , pp. 214-221
    • Trenk, D.1
  • 73
    • 57549090390 scopus 로고    scopus 로고
    • Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: Results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomised study
    • Aleil B, et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomised study. JACC Cardiovasc Interv 2008; 1: 631-638.
    • (2008) JACC Cardiovasc Interv , vol.1 , pp. 631-638
    • Aleil, B.1
  • 74
    • 62549101321 scopus 로고    scopus 로고
    • Randomised comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomised study
    • Jeong YH, et al. randomised comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomised study. J Am Coll Cardiol 2009; 53: 1101-1109.
    • (2009) J am Coll Cardiol , vol.53 , pp. 1101-1109
    • Jeong, Y.H.1
  • 75
    • 79955116606 scopus 로고    scopus 로고
    • High doses of clopidogrel to overcome genetic resistance: The randomised crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)
    • Collet JP, et al. High doses of clopidogrel to overcome genetic resistance: the randomised crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACC Cardiovasc Interv 2011; 4: 392-402.
    • (2011) JACC Cardiovasc Interv , vol.4 , pp. 392-402
    • Collet, J.P.1
  • 76
    • 67650745975 scopus 로고    scopus 로고
    • Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: Results from the double-blind, prospective, randomised Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study
    • Valgimigli M, et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomised Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009; 119: 3215-3222.
    • (2009) Circulation , vol.119 , pp. 3215-3222
    • Valgimigli, M.1
  • 77
    • 57549099501 scopus 로고    scopus 로고
    • Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: A prospective, randomised study
    • Cuisset T, et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomised study. JACC Cardiovasc Interv 2008; 1: 649-653.
    • (2008) JACC Cardiovasc Interv , vol.1 , pp. 649-653
    • Cuisset, T.1
  • 78
    • 79952598836 scopus 로고    scopus 로고
    • Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomised trial
    • Price MJ, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomised trial. J Am Med Assoc 2011; 305: 1097-1105.
    • (2011) J am Med Assoc , vol.305 , pp. 1097-1105
    • Price, M.J.1
  • 79
    • 84861857758 scopus 로고    scopus 로고
    • A randomised trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: Results of the TRIGGERPCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study
    • Trenk D, et al. A randomised trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGERPCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012; 59: 2159-2164.
    • (2012) J am Coll Cardiol , vol.59 , pp. 2159-2164
    • Trenk, D.1
  • 80
    • 84868332790 scopus 로고    scopus 로고
    • Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularisation: The TRILOGY ACS platelet function substudy
    • Gurbel PA, et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularisation: the TRILOGY ACS platelet function substudy. J Am Med Assoc 2012; 308: 1785-1794.
    • (2012) J am Med Assoc , vol.308 , pp. 1785-1794
    • Gurbel, P.A.1
  • 81
    • 84883281361 scopus 로고    scopus 로고
    • Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis
    • Aradi D, et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol 2013; 167: 2140-2148.
    • (2013) Int J Cardiol , vol.167 , pp. 2140-2148
    • Aradi, D.1
  • 82
    • 84870032410 scopus 로고    scopus 로고
    • Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting
    • Collet JP, et al. Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting. N Engl J Med 2012; 367: 2100-2109.
    • (2012) N Engl J Med , vol.367 , pp. 2100-2109
    • Collet, J.P.1
  • 83
    • 84877021553 scopus 로고    scopus 로고
    • A large-scale, prospective, multicenter registry examining the relationship between platelet responsiveness and stent thrombosis after des implantation. Results from the ADAPT-DES study
    • Abstract LBCT
    • Stone G. A large-scale, prospective, multicenter registry examining the relationship between platelet responsiveness and stent thrombosis after des implantation. Results from the ADAPT-DES study. J Am Coll Cardiol 2011; 58 (Supplement B): Abstract LBCT.
    • (2011) J am Coll Cardiol , vol.58
    • Stone, G.1
  • 84
    • 84870032410 scopus 로고    scopus 로고
    • Bedside monitoring to adjust antiplatelet therapy for coronary stenting
    • Collet JP, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100-2109.
    • (2012) N Engl J Med , vol.367 , pp. 2100-2109
    • Collet, J.P.1
  • 85
    • 34250703278 scopus 로고    scopus 로고
    • Resistance to antiplatelet drugs: Molecular mechanisms and laboratory detection
    • Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost 2007; 5 (Suppl 1): 230-237.
    • (2007) J Thromb Haemost , vol.5 , pp. 230-237
    • Cattaneo, M.1
  • 86
    • 84874759680 scopus 로고    scopus 로고
    • Hirudin anticoagulation allows more rapid determination of P2Y(1)(2) inhibition by the VerifyNow P2Y12 assay
    • Sumaya W, et al. Hirudin anticoagulation allows more rapid determination of P2Y(1)(2) inhibition by the VerifyNow P2Y12 assay. Thromb Haemost 2013; 109: 550-555.
    • (2013) Thromb Haemost , vol.109 , pp. 550-555
    • Sumaya, W.1
  • 87
    • 79951782413 scopus 로고    scopus 로고
    • Functional testing methods for the antiplatelet effects of aspirin
    • Schror K, et al. Functional testing methods for the antiplatelet effects of aspirin. Biomarkers Med 2011; 5: 31-42.
    • (2011) Biomarkers Med , vol.5 , pp. 31-42
    • Schror, K.1
  • 88
    • 0035469889 scopus 로고    scopus 로고
    • Differential inhibition of adenosine diphosphate-versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics
    • Weber AA, Schror K. Differential inhibition of adenosine diphosphate-versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics. Blood 2001; 98: 1619-1621.
    • (2001) Blood , vol.98 , pp. 1619-1621
    • Weber, A.A.1    Schror, K.2
  • 89
    • 84925376426 scopus 로고    scopus 로고
    • Clopidogrel Genotyping for Antiplatelet Guidance in MI Stenting: Maybe Reduced Ischaemic Risk
    • Nov. 6, 2013
    • Clopidogrel Genotyping for Antiplatelet Guidance in MI Stenting: Maybe Reduced Ischaemic Risk. Medscape 2013; Nov. 6, 2013.
    • (2013) Medscape
  • 90
    • 79952435294 scopus 로고    scopus 로고
    • The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy
    • Gurbel PA, et al. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Am Heart J 2011; 161: 598-604.
    • (2011) Am Heart J , vol.161 , pp. 598-604
    • Gurbel, P.A.1
  • 91
    • 84899713032 scopus 로고    scopus 로고
    • Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: Impact of prasugrel and high-dose clopidogrel
    • Aradi D, et al. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol 2014; 63: 1061-1070.
    • (2014) J am Coll Cardiol , vol.63 , pp. 1061-1070
    • Aradi, D.1
  • 92
    • 84884870121 scopus 로고    scopus 로고
    • Why have studies of tailored anti-platelet therapy failed so far?
    • Siller-Matula JM, Jilma B. Why have studies of tailored anti-platelet therapy failed so far? Thromb Haemost 2013; 110: 628-631.
    • (2013) Thromb Haemost , vol.110 , pp. 628-631
    • Siller-Matula, J.M.1    Jilma, B.2
  • 93
    • 35549008493 scopus 로고    scopus 로고
    • Platelet function monitoring in patients with coronary artery disease
    • Gurbel PA, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822-1834.
    • (2007) J am Coll Cardiol , vol.50 , pp. 1822-1834
    • Gurbel, P.A.1
  • 94
    • 84896701814 scopus 로고    scopus 로고
    • Lower Mortality Following Pulmonary Adverse Events and Sepsis with Ticagrelor Compared to Clopidogrel in the PLATO Study
    • Epub ahead of print
    • Storey RF, et al. Lower Mortality Following Pulmonary Adverse Events and Sepsis with Ticagrelor Compared to Clopidogrel in the PLATO Study. Platelets 2013; Epub ahead of print.
    • (2013) Platelets
    • Storey, R.F.1
  • 95
    • 80455149677 scopus 로고    scopus 로고
    • Diurnal variation in platelet inhibition by clopidogrel
    • Kozinski M, et al. Diurnal variation in platelet inhibition by clopidogrel. Platelets 2011; 22: 579-587.
    • (2011) Platelets , vol.22 , pp. 579-587
    • Kozinski, M.1
  • 96
    • 59849103903 scopus 로고    scopus 로고
    • Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report
    • Kozinski M, et al. Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report. Cardiol J 2008; 15: 530-536.
    • (2008) Cardiol J , vol.15 , pp. 530-536
    • Kozinski, M.1
  • 97
    • 63049117527 scopus 로고    scopus 로고
    • The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation
    • Siller-Matula JM, et al. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation. Thromb Res 2009; 123: 874-880.
    • (2009) Thromb Res , vol.123 , pp. 874-880
    • Siller-Matula, J.M.1
  • 98
    • 84874357792 scopus 로고    scopus 로고
    • Bedside monitoring of antiplatelet therapy for coronary stenting
    • De Caterina R, et al. Bedside monitoring of antiplatelet therapy for coronary stenting. N Engl J Med 2013; 368: 871.
    • (2013) N Engl J Med , vol.368 , pp. 871
    • De Caterina, R.1
  • 99
    • 84866368808 scopus 로고    scopus 로고
    • 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (Updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
    • Jneid H, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012; 60: 645-681.
    • (2012) J am Coll Cardiol , vol.60 , pp. 645-681
    • Jneid, H.1
  • 100
    • 84856158305 scopus 로고    scopus 로고
    • ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
    • Hamm CW, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
    • (2011) Eur Heart J , vol.32 , pp. 2999-3054
    • Hamm, C.W.1
  • 101
    • 84855992555 scopus 로고    scopus 로고
    • ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation?American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
    • Levine GN, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation?American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58: e44-122.
    • (2011) J am Coll Cardiol , vol.58 , pp. e44-e122
    • Levine, G.N.1
  • 102
    • 70149101223 scopus 로고    scopus 로고
    • Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
    • 102.Wallentin L, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2009; 361: 1045-1057.
    • (2009) N Engl J Med , vol.361 , pp. 1045-1057
    • Wallentin, L.1
  • 103
    • 36148983750 scopus 로고    scopus 로고
    • Prasugrel versus clopidogrel in patients with acute coronary syndromes
    • 103.Wiviott SD, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
    • (2007) N Engl J Med , vol.357 , pp. 2001-2015
    • Wiviott, S.D.1
  • 105
    • 84894361062 scopus 로고    scopus 로고
    • 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions
    • O’Gara PT, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv 2013; 82: E1-27.
    • (2013) Catheter Cardiovasc Interv , vol.82 , pp. E1-E27
    • O’Gara, P.T.1
  • 106
    • 84879663575 scopus 로고    scopus 로고
    • Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes
    • Huber K, Lip GY. Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes. Thromb Haemost 2013; 110: 11-13.
    • (2013) Thromb Haemost , vol.110 , pp. 11-13
    • Huber, K.1    Lip, G.Y.2
  • 107
    • 33947328091 scopus 로고    scopus 로고
    • Thienopyridines in cardiovascular disease: Focus on clopidogrel resistance
    • Siller-Matula J, et al. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385-393.
    • (2007) Thromb Haemost , vol.97 , pp. 385-393
    • Siller-Matula, J.1
  • 108
    • 82955203400 scopus 로고    scopus 로고
    • Prevalence of contraindications and conditions for precaution for prasugrel administration in a real world acute coronary syndrome population
    • Alexopoulos D, et al. Prevalence of contraindications and conditions for precaution for prasugrel administration in a real world acute coronary syndrome population. J Thromb Thrombolysis 2011; 32: 328-333.
    • (2011) J Thromb Thrombolysis , vol.32 , pp. 328-333
    • Alexopoulos, D.1
  • 109
    • 55449137355 scopus 로고    scopus 로고
    • CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation
    • Geisler T, et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008; 9: 1251-1259.
    • (2008) Pharmacogenomics , vol.9 , pp. 1251-1259
    • Geisler, T.1
  • 110
    • 77249113768 scopus 로고    scopus 로고
    • Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation
    • Breet NJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754-762.
    • (2010) J am Med Assoc , vol.303 , pp. 754-762
    • Breet, N.J.1
  • 111
    • 79961046361 scopus 로고    scopus 로고
    • Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events
    • Freynhofer MK, et al. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events. Thromb Haemost 2011; 106: 230-239.
    • (2011) Thromb Haemost , vol.106 , pp. 230-239
    • Freynhofer, M.K.1
  • 112
    • 34447636769 scopus 로고    scopus 로고
    • Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events
    • Bonello L, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007; 5: 1630-1636.
    • (2007) J Thromb Haemost , vol.5 , pp. 1630-1636
    • Bonello, L.1
  • 113
    • 77956654443 scopus 로고    scopus 로고
    • Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel
    • Bal Dit Sollier C, et al. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel. Thromb Haemost 2010; 104: 571-581.
    • (2010) Thromb Haemost , vol.104 , pp. 571-581
    • Bal Dit Sollier, C.1
  • 114
    • 84876130984 scopus 로고    scopus 로고
    • Methodological considerations for the assessment of ADP induced platelet aggregation using the Multiplate(R) analyser
    • Johnston LR, et al. Methodological considerations for the assessment of ADP induced platelet aggregation using the Multiplate(R) analyser. Platelets 2013; 24: 303-307.
    • (2013) Platelets , vol.24 , pp. 303-307
    • Johnston, L.R.1
  • 115
    • 82555161672 scopus 로고    scopus 로고
    • Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity
    • Capranzano P, et al. Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. Thromb Haemost 2011; 106: 1149-1157.
    • (2011) Thromb Haemost , vol.106 , pp. 1149-1157
    • Capranzano, P.1
  • 116
    • 84655161920 scopus 로고    scopus 로고
    • Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus
    • Ferreiro JL, et al. Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus. Rev Esp Cardiol 2011; 65: 105-106.
    • (2011) Rev Esp Cardiol , vol.65 , pp. 105-106
    • Ferreiro, J.L.1
  • 117
    • 84904607606 scopus 로고    scopus 로고
    • Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up
    • Epub ahead of print
    • Kozinski M, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. Cardiol J 2014; Epub ahead of print.
    • (2014) Cardiol J
    • Kozinski, M.1
  • 118
    • 51749097093 scopus 로고    scopus 로고
    • Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction
    • Matetzky S, et al. Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction. Am J Cardiol 2008; 102: 524-529.
    • (2008) Am J Cardiol , vol.102 , pp. 524-529
    • Matetzky, S.1
  • 119
    • 73149118496 scopus 로고    scopus 로고
    • The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: First experience in patients
    • Gurbel PA, et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J Thromb Haemost 2010; 8: 43-53.
    • (2010) J Thromb Haemost , vol.8 , pp. 43-53
    • Gurbel, P.A.1
  • 120
    • 77950508416 scopus 로고    scopus 로고
    • Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: The RESPOND study
    • Gurbel PA, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121: 1188-1199.
    • (2010) Circulation , vol.121 , pp. 1188-1199
    • Gurbel, P.A.1
  • 121
    • 38949133119 scopus 로고    scopus 로고
    • How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification
    • Neubauer H, et al. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Thromb Haemost 2008; 99: 357-362.
    • (2008) Thromb Haemost , vol.99 , pp. 357-362
    • Neubauer, H.1
  • 122
    • 84860538806 scopus 로고    scopus 로고
    • Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): A prospective, randomised, proof-of-concept trial
    • Roberts JD, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012; 379: 1705-1711.
    • (2012) Lancet , vol.379 , pp. 1705-1711
    • Roberts, J.D.1
  • 123
    • 79955093619 scopus 로고    scopus 로고
    • Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype
    • Kim IS, et al. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. JACC Cardiovasc Interv 2011; 4: 381-391.
    • (2011) JACC Cardiovasc Interv , vol.4 , pp. 381-391
    • Kim, I.S.1
  • 124
    • 78650048685 scopus 로고    scopus 로고
    • Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention
    • Hwang SJ, et al. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2010; 3: 450-459.
    • (2010) Circ Cardiovasc Interv , vol.3 , pp. 450-459
    • Hwang, S.J.1
  • 125
    • 0038649988 scopus 로고    scopus 로고
    • Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity
    • Gurbel PA, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
    • (2003) Circulation , vol.107 , pp. 2908-2913
    • Gurbel, P.A.1
  • 126
    • 77949297362 scopus 로고    scopus 로고
    • Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel
    • Bouman HJ, et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 2010; 8: 482-488.
    • (2010) J Thromb Haemost , vol.8 , pp. 482-488
    • Bouman, H.J.1
  • 127
    • 79956315296 scopus 로고    scopus 로고
    • High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention
    • Breet NJ, et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart 2011; 97: 983-990.
    • (2011) Heart , vol.97 , pp. 983-990
    • Breet, N.J.1
  • 128
    • 70449474088 scopus 로고    scopus 로고
    • The influence of clinical characteristics, laboratory and inflammatory markers on ’high on-treatment platelet reactivity’ as measured with different platelet function tests
    • Elsenberg EH, et al. The influence of clinical characteristics, laboratory and inflammatory markers on ’high on-treatment platelet reactivity’ as measured with different platelet function tests. Thromb Haemost 2009; 102: 719-727.
    • (2009) Thromb Haemost , vol.102 , pp. 719-727
    • Elsenberg, E.H.1
  • 129
    • 35548957533 scopus 로고    scopus 로고
    • Assessment of clopidogrel responsiveness: Measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients
    • Gurbel PA, et al. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thromb Res 2007; 121: 107-115.
    • (2007) Thromb Res , vol.121 , pp. 107-115
    • Gurbel, P.A.1
  • 130
    • 38349168418 scopus 로고    scopus 로고
    • A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry
    • Jakubowski JA, et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 2008; 99: 215-222.
    • (2008) Thromb Haemost , vol.99 , pp. 215-222
    • Jakubowski, J.A.1
  • 131
    • 77951644504 scopus 로고    scopus 로고
    • Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y
    • Linnemann B, et al. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. Ann Hematol 2010; 89: 597-605.
    • (2010) Ann Hematol , vol.89 , pp. 597-605
    • Linnemann, B.1
  • 132
    • 77955449383 scopus 로고    scopus 로고
    • Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients
    • Paniccia R, et al. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost 2010; 104: 287-292.
    • (2010) Thromb Haemost , vol.104 , pp. 287-292
    • Paniccia, R.1
  • 133
    • 38349090725 scopus 로고    scopus 로고
    • Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment
    • Sibbing D, et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008; 99: 121-126.
    • (2008) Thromb Haemost , vol.99 , pp. 121-126
    • Sibbing, D.1
  • 134
    • 68649097104 scopus 로고    scopus 로고
    • Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects
    • Li YG, et al. Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. Platelets 2009; 20: 316-327.
    • (2009) Platelets , vol.20 , pp. 316-327
    • Li, Y.G.1
  • 135
    • 84908512459 scopus 로고    scopus 로고
    • Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-Egitromb
    • Epub ahead of print
    • Komosa A, et al. Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-Egitromb. Platelets 2014; Epub ahead of print.
    • (2014) Platelets
    • Komosa, A.1
  • 136
    • 84879099050 scopus 로고    scopus 로고
    • Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin
    • Siller-Matula JM, et al. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Int J Cardiol 2013; 167: 430-435.
    • (2013) Int J Cardiol , vol.167 , pp. 430-435
    • Siller-Matula, J.M.1
  • 137
    • 84881314865 scopus 로고    scopus 로고
    • Platelet Inhibition by Abciximab Bolus-Only Administration and Oral ADP Receptor Antagonist Loading in Acute Coronary Syndrome Patients: The Blocking and Bridging Strategy
    • Christ G, et al. Platelet Inhibition by Abciximab Bolus-Only Administration and Oral ADP Receptor Antagonist Loading in Acute Coronary Syndrome Patients: The Blocking and Bridging Strategy. Thromb Res 2013; 132: e36-e41.
    • (2013) Thromb Res , vol.132 , pp. e36-e41
    • Christ, G.1
  • 138
    • 84866789111 scopus 로고    scopus 로고
    • Effects of prasugrel on platelet inhibition during systemic endotoxaemia: A randomised controlled trial
    • Spiel AO, et al. Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomised controlled trial. Clin Sci 2012; 123: 591-600.
    • (2012) Clin Sci , vol.123 , pp. 591-600
    • Spiel, A.O.1
  • 139
    • 84858690837 scopus 로고    scopus 로고
    • ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion
    • Siller-Matula JM, et al. ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. Arterioscler Thromb Vasc Biol 2012; 32: 902-909.
    • (2012) Arterioscler Thromb Vasc Biol , vol.32 , pp. 902-909
    • Siller-Matula, J.M.1
  • 140
    • 74249119049 scopus 로고    scopus 로고
    • Pantoprazole may enhance antiplatelet effect of entericcoated aspirin in patients with acute coronary syndrome
    • Kasprzak M, et al. Pantoprazole may enhance antiplatelet effect of entericcoated aspirin in patients with acute coronary syndrome. Cardiol J 2009; 16: 535-544.
    • (2009) Cardiol J , vol.16 , pp. 535-544
    • Kasprzak, M.1
  • 141
    • 74249104162 scopus 로고    scopus 로고
    • Clopidogrel response status assessed with Multiplate point-ofcare analysis and the incidence and timing of stent thrombosis over six months following coronary stenting
    • Sibbing D, et al. Clopidogrel response status assessed with Multiplate point-ofcare analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103: 151-159.
    • (2010) Thromb Haemost , vol.103 , pp. 151-159
    • Sibbing, D.1
  • 142
    • 36949000480 scopus 로고    scopus 로고
    • The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis
    • Blindt R, et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007; 98: 1329-1334.
    • (2007) Thromb Haemost , vol.98 , pp. 1329-1334
    • Blindt, R.1
  • 143
    • 29344466941 scopus 로고    scopus 로고
    • Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: The role of dual drug resistance
    • Lev EI, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006; 47: 27-33.
    • (2006) J am Coll Cardiol , vol.47 , pp. 27-33
    • Lev, E.I.1
  • 144
    • 34548722718 scopus 로고    scopus 로고
    • Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-STsegment elevation acute coronary syndrome
    • Cuisset T, et al. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-STsegment elevation acute coronary syndrome. Thromb Res 2007; 120: 893-899.
    • (2007) Thromb Res , vol.120 , pp. 893-899
    • Cuisset, T.1
  • 145
    • 79961114506 scopus 로고    scopus 로고
    • Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44
    • Frelinger AL, 3rd, et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost 2011; 106: 219-226.
    • (2011) Thromb Haemost , vol.106 , pp. 219-226
    • Frelinger, A.L.1
  • 146
    • 44749084716 scopus 로고    scopus 로고
    • Relation of low response to clopidogrel assessed with point-ofcare assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris
    • Cuisset T, et al. Relation of low response to clopidogrel assessed with point-ofcare assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardiol 2008; 101: 1700-1703.
    • (2008) Am J Cardiol , vol.101 , pp. 1700-1703
    • Cuisset, T.1
  • 147
    • 38949094987 scopus 로고    scopus 로고
    • The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y(12) inhibition levels following prasugrel and clopidogrel administration
    • Jakubowski JA, et al. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y(12) inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 2008; 99: 409-415.
    • (2008) Thromb Haemost , vol.99 , pp. 409-415
    • Jakubowski, J.A.1
  • 148
    • 44949173754 scopus 로고    scopus 로고
    • Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
    • Price MJ, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000.
    • (2008) Eur Heart J , vol.29 , pp. 992-1000
    • Price, M.J.1
  • 149
    • 77951679429 scopus 로고    scopus 로고
    • The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo
    • Mayr FB, et al. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion 2010; 50: 1079-1087.
    • (2010) Transfusion , vol.50 , pp. 1079-1087
    • Mayr, F.B.1
  • 150
    • 70350464420 scopus 로고    scopus 로고
    • Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers
    • Siller-Matula JM, et al. Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. Thromb Haemost 2009; 102: 397-403.
    • (2009) Thromb Haemost , vol.102 , pp. 397-403
    • Siller-Matula, J.M.1
  • 151
    • 33845765298 scopus 로고    scopus 로고
    • Monitoring survival and function of transfused platelets in Bernard-Soulier syndrome by flow cytometry and a cone and plate(Let) analyzer (Impact-R)
    • Panzer S, et al. Monitoring survival and function of transfused platelets in Bernard-Soulier syndrome by flow cytometry and a cone and plate(let) analyzer (Impact-R). Transfusion 2007; 47: 103-106.
    • (2007) Transfusion , vol.47 , pp. 103-106
    • Panzer, S.1
  • 152
    • 77955897278 scopus 로고    scopus 로고
    • Single dose granulocyte colony-stimulating factor markedly enhances shear-dependent platelet function in humans
    • Spiel AO, et al. Single dose granulocyte colony-stimulating factor markedly enhances shear-dependent platelet function in humans. Platelets 2010; 21: 464-469.
    • (2010) Platelets , vol.21 , pp. 464-469
    • Spiel, A.O.1
  • 153
    • 34547760330 scopus 로고    scopus 로고
    • A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease
    • Lordkipanidze M, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702-1708.
    • (2007) Eur Heart J , vol.28 , pp. 1702-1708
    • Lordkipanidze, M.1
  • 154
    • 77953160638 scopus 로고    scopus 로고
    • A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease
    • Grove EL, et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103: 1245-1253.
    • (2010) Thromb Haemost , vol.103 , pp. 1245-1253
    • Grove, E.L.1
  • 155
    • 73949093109 scopus 로고    scopus 로고
    • Association of cyclooxygenase-1-dependent and-independent platelet function assays with adverse clinical outcomes in aspirintreated patients presenting for cardiac catheterisation
    • Frelinger AL, 3rd, et al. Association of cyclooxygenase-1-dependent and-independent platelet function assays with adverse clinical outcomes in aspirintreated patients presenting for cardiac catheterisation. Circulation 2009; 120: 2586-2596.
    • (2009) Circulation , vol.120 , pp. 2586-2596
    • Frelinger, A.L.1
  • 156
    • 27644536235 scopus 로고    scopus 로고
    • Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POST-STENTING Study
    • Gurbel PA, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820-1826.
    • (2005) J am Coll Cardiol , vol.46 , pp. 1820-1826
    • Gurbel, P.A.1
  • 157
    • 33846837282 scopus 로고    scopus 로고
    • Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate?
    • Bliden KP, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49: 657-666.
    • (2007) J am Coll Cardiol , vol.49 , pp. 657-666
    • Bliden, K.P.1
  • 158
    • 2342489360 scopus 로고    scopus 로고
    • A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation
    • Craft RM, et al. A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 2004; 143: 301-309.
    • (2004) J Lab Clin Med , vol.143 , pp. 301-309
    • Craft, R.M.1
  • 159
    • 61649091347 scopus 로고    scopus 로고
    • Evaluation of the Platelet Mapping Assay on rotational thromboelastometry ROTEM
    • Scharbert G, et al. Evaluation of the Platelet Mapping Assay on rotational thromboelastometry ROTEM. Platelets 2009; 20: 125-130.
    • (2009) Platelets , vol.20 , pp. 125-130
    • Scharbert, G.1
  • 160
    • 84860789698 scopus 로고    scopus 로고
    • Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: The timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study
    • Mahla E, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 2012; 5: 261-269.
    • (2012) Circ Cardiovasc Interv , vol.5 , pp. 261-269
    • Mahla, E.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.